Latest Cmece Podcast Episodes
S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer
Hematology / Oncology @Point of Care Podcasts - December 29, 2023 18:00 - 26 minutesOur faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them. Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE information, download the transcript, and complete the...
S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer
Hematology / Oncology @Point of Care Podcasts - December 29, 2023 17:58 - 30 minutesIn this episode our faculty take a look at the clinical trial data on HER3-directed therapies for breast and lung cancer. Visit www.morningcommutepodcast.com/HER3Agnostic2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME...
S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?
Hematology / Oncology @Point of Care Podcasts - December 29, 2023 17:56 - 25 minutesIn this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar. Visit www.morningcommutepodcast.com/HER3Agnostic1 to view the activity and CME/CE information, download the tr...
S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits
Hematology / Oncology @Point of Care Podcasts - November 30, 2023 17:02 - 28 minutesIn this episode our faculty take a look at the ins and outs of molecular testing in patients with HR+ positive breast cancer. Visit www.morningcommutepodcast.com/HRPositiveBreast3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to ...
S18:E2 – Morning Commute Podcast: Embracing HER2-Low, Trop2-Directed, and Other Newer Approaches to HR-Positive Breast Cancer
Hematology / Oncology @Point of Care Podcasts - November 30, 2023 16:59 - 30 minutesIn this podcast, our faculty take a look at some of the clinical data behind the newer treatment strategies for HR-positive breast cancer as well as how to address and manage some associated adverse events. Visit www.morningcommutepodcast.com/HRPositiveBreast2 to view the activity and CME/CE in...
S18:E1 – Morning Commute Podcast: An AKTor and Supporting Cast Take the Stage in HR+ Breast Cancer
Hematology / Oncology @Point of Care Podcasts - November 30, 2023 16:58 - 23 minutesIn this podcast, our faculty discuss some newer treatment approaches for patients with HR-positive breast cancer including PI3K inhibition, AKT inhibition, and oral selective estrogen receptor down regulators. Visit www.morningcommutepodcast.com/HRPositiveBreast1 to view the activity and CME/CE...
S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia
Hematology / Oncology @Point of Care Podcasts - November 15, 2023 17:25 - 34 minutesFLT3-inhibitors, such as quizartinib, are changing the treatment paradigm for AML, in this podcast, our faculty take a look at the drug class, how they are used in AML, and how to manage any treatment-related adverse events. Visit www.morningcommutepodcast.com/aml4 to view the activity and CME/...
S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib
Hematology / Oncology @Point of Care Podcasts - November 15, 2023 17:24 - 31 minutesThe treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to...
S17:E2 – Morning Commute Podcast: Treatment Options for Newly Diagnosed AML Patients
Hematology / Oncology @Point of Care Podcasts - November 15, 2023 17:22 - 33 minutesIn this podcast our faculty discuss the latest treatment options for AML that target FLT3 mutations: midostaurin, gilteritinib, and the new kid on the block, quizartinib. Visit www.morningcommutepodcast.com/aml2 to view the activity and CME/CE information, download the transcript, and complete ...
S17:E1 – Morning Commute Podcast: The Molecular Landscape of FLT3 Mutations in AML
Hematology / Oncology @Point of Care Podcasts - November 15, 2023 17:12 - 26 minutesOur faculty discuss the importance of biomarker testing for FLT3 and FLT3-ITD and the prognostic impact for these patients, especially now that there are therapies targeting these mutations. Visit www.morningcommutepodcast.com/aml1 to view the activity and CME/CE information, download the trans...
S16:E3 – Oncology Morning Commute: Sequencing Therapies in Endometrial Cancer Beyond the First-line Setting
Hematology / Oncology @Point of Care Podcasts - July 26, 2023 01:10 - 23 minutesIn this podcast of our three-part series, our faculty continue their discussion on the treatment of endometrial cancer, this time looking at some of the key data on combination therapies as well as associated adverse events and how to handle them. Visit www.MorningCommutePodcast.com/Endometrial...
S16:E2 – Oncology Morning Commute: Is Immunotherapy Replacing Chemo in the First-Line Treatment Setting for Endometrial Cancer?
Hematology / Oncology @Point of Care Podcasts - December 31, 2022 02:05 - 26 minutesIn this episode of our three-part series on endometrial cancer, our faculty continue their discussion by turning to some of the ongoing, and some may say groundbreaking, clinical trials for the use of immunotherapies in the first-line setting. Visit www.MorningCommutePodcast.com/Endometrial4 to...
S16:E1 – Oncology Morning Commute: Understanding the Heterogeneity of Endometrial Cancer
Hematology / Oncology @Point of Care Podcasts - December 31, 2022 02:00 - 25 minutesIn this podcast, our faculty discuss the heterogeneity of endometrial cancer and its four molecular classifications. How do these classifications help determine patient treatment plans? Visit www.MorningCommutePodcast.com/Endometrial3 to view the activity and CME/CE information, download the tr...
S15:E3 – Oncology Morning Commute: HER2+ CRC Therapies in Clinical Practice
Hematology / Oncology @Point of Care Podcasts - December 23, 2022 08:03 - 26 minutesIn this final podcast of our 3-part series, our faculty take their discussion of metastatic colorectal cancer and HER2-targeted therapies to the clinical level and share some patient cases. You don't want to miss these clinical pearls. Visit http://www.MorningCommutePodcast.com/CRC3 to view t...
S15:E2 – Oncology Morning Commute: Emerging Data on HER2-Positive Colorectal Cancer Therapies
Hematology / Oncology @Point of Care Podcasts - December 23, 2022 08:02 - 25 minutesIn this podcast, our faculty discuss HER2-positive colorectal cancer. HER2 has long been associated as a biomarker and treatment target for breast cancer, but now it is also a target in some colorectal cancers. Dr. John Marshall and Dr. Sunni Kim take a look at some of the recent clinical data o...
S15:E1 – Oncology Morning Commute: Recognition of Actionable Biomarkers in Colorectal Cancer
Hematology / Oncology @Point of Care Podcasts - December 23, 2022 08:01 - 24 minutesIn this first podcast of our three-part series, our faculty discuss biomarkers for colorectal cancer including HER2. Are you aware of the current guideline recommendations for biomarker testing in colorectal cancer? Visit http://www.MorningCommutePodcast.com/CRC1 to view the activity and CME/...
S14:E3 – Oncology Morning Commute: How Can Physicians Use Best Clinical Judgment to Determine Core Drivers for Cancer Screening?
Hematology / Oncology @Point of Care Podcasts - December 22, 2022 11:03 - 22 minutesIn this final podcast of our 3-part series, our faculty continue their discussion on multicancer early detection tests, this time turning to how to incorporate these tests into clinical practice. Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect3 to view the activity and CME/CE inf...
S14:E2 – Oncology Morning Commute: A Review of the Science Behind Multicancer Early Detection Tests
Hematology / Oncology @Point of Care Podcasts - December 22, 2022 08:02 - 24 minutesIn the second episode of our podcast series on early cancer detection, our faculty take a closer look at multicancer early detection tests and the groundbreaking PATHFINDER study that so far is showing impressive data. Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect2 to view the ac...
S14:E1 – Oncology Morning Commute: New Approaches to Testing Patients for Cancer
Hematology / Oncology @Point of Care Podcasts - December 22, 2022 08:01In this podcast, our faculty discuss new methods of detecting cancer, including liquid biopsy and blood based, multicancer early detection tests. Can one blood sample provide accurate screening for many cancers? Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect1 to view the activity ...
S13:E3 – Oncology Morning Commute: What’s Next in Using PARP Inhibitors for Patients With Ovarian Cancer?
Hematology / Oncology @Point of Care Podcasts - December 16, 2022 04:15 - 29 minutesIn this final podcast of our three-part series, our faculty look at some of the latest findings on PARP inhibitors as well as what is on the horizon. They also tackle the topic of disparities in care for patients with ovarian cancer and how clinical trials can address this. Visit http://www.Mor...
S13:E2 – Oncology Morning Commute: Managing Adverse Events That Occur With PARP Inhibition Therapies—What Your Patients Need to Know
Hematology / Oncology @Point of Care Podcasts - December 16, 2022 04:11In this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for these therapies and how are adverse events managed for the best outcomes? Visit http://www.MorningCommutePodcast.com/OvarianCancer2 to view the ac...
S13:E1 – Oncology Morning Commute: Patient Selection for Treatment With PARP Inhibitors in Ovarian Cancer
Hematology / Oncology @Point of Care Podcasts - December 16, 2022 04:08 - 29 minutesWhat is the history behind the development of PARP inhibitors for the treatment of ovarian cancer and how have they influenced recent guideline changes regarding their use? Our faculty discuss this and more in the first podcast of the three-part series on PARP inhibitors and ovarian cancer. V...
S12:E3 – Oncology Morning Commute: Shifting Treatment Sequences in the Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape
Hematology / Oncology @Point of Care Podcasts - November 23, 2022 02:49 - 22 minutesIn the final episode of our series, our faculty discuss the changing treatment landscape for diffuse large B-cell lymphoma. With more and more options, the paradigm is shifting and that's good news. Visit http://www.MorningCommutePodcast.com/BCell3 to view the activity and CME/CE information, d...
S12:E2 – Oncology Morning Commute: Antibody-Drug Conjugates and the Changing Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape
Hematology / Oncology @Point of Care Podcasts - November 23, 2022 02:47 - 22 minutesWhat are the antibody-drug conjugate treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma? In this podcast our faculty look at key trial data as well as treatment management for this disease. Visit http://www.MorningCommutePodcast.com/BCell2 to view the activ...
S12:E1 – Oncology Morning Commute: A Primer on B-Cell Targets in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hematology / Oncology @Point of Care Podcasts - November 23, 2022 02:43 - 21 minutesIn this podcast, our faculty discuss relapsed/refractory diffuse large B-cell lymphoma, how refractory disease is defined, and the role of the new antibody-based therapies in relapsed/refractory disease. Visit http://www.MorningCommutePodcast.com/BCell1 to view the activity and CME/CE informati...
S11:E6 – Oncology Morning Commute: Have I Got a Follicular Lymphoma Trial for You
Hematology / Oncology @Point of Care Podcasts - October 01, 2022 01:37 - 23 minutesIn this final episode, our faculty discuss clinical trials that are in progress, the importance of the clinical trial process, and how they benefit patients and help move the needle on new and promising treatments. Visit http://www.MorningCommutePodcast.com/FL6 to view the activity and CME/CE i...
S11:E5 – Oncology Morning Commute: Safety First in Follicular Lymphoma
Hematology / Oncology @Point of Care Podcasts - October 01, 2022 01:35 - 24 minutesIn this podcast, our faculty discuss the major classes of treatment for follicular lymphoma, including outcomes and managing the expected toxicities. Visit http://www.MorningCommutePodcast.com/FL5 to view the activity and CME/CE information, download the transcript, and complete the post-test a...
S11:E4 – Oncology Morning Commute: Making the Case for Follicular Lymphoma Therapy
Hematology / Oncology @Point of Care Podcasts - October 01, 2022 01:26How is the best way to select and sequence follicular lymphoma therapies? In this episode, our faculty discuss this and more. Visit http://www.MorningCommutePodcast.com/FL4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CM...
S11:E3 – Oncology Morning Commute: Follicular Lymphoma—Haven't We Met Before?
Hematology / Oncology @Point of Care Podcasts - October 01, 2022 01:25 - 25 minutesIn our third podcast in this series, our faculty take a look at third-line treatment options for follicular lymphoma patients. Visit http://www.MorningCommutePodcast.com/FL3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn C...
S11:E2 – Oncology Morning Commute: What Can We Do About Early Relapsing Follicular Lymphoma?
Hematology / Oncology @Point of Care Podcasts - October 01, 2022 01:20 - 26 minutesIn this second podcast of our series, our faculty continue their discussion of follicular lymphoma and its treatment, particularly for those patients who progress within the first 24 months, the progression of disease within 2 years (POD24). What is known about predictors of progression and what...
Related Cmece Topics